Onconova Therapeutics, Inc. (ONTX) financial statements (2022 and earlier)

Company profile

Business Address 375 PHEASANT RUN
NEWTOWN, PA 18940
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments     21,40019,799
Cash and cash equivalents     21,40019,799
Restricted cash and investments     5050
Receivables2837983559311,504
Prepaid expense282353189166181350451
Other current assets35180140687773195
Other undisclosed current assets55,08519,21423,04717,4964,5861,1651,186
Total current assets:55,43019,78423,47417,7654,90323,06923,185
Noncurrent Assets
Property, plant and equipment385250964152248
Other noncurrent assets10150150149121212
Total noncurrent assets:4820220015876164260
TOTAL ASSETS:55,47819,98623,67417,9234,97923,23323,445
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,8899,7958,0665,9277,6097,1314,165
Accounts payable2,7574,8334,2714,0396,1865,3233,421
Accrued liabilities3,1324,9623,795238165235306
Employee-related liabilities   1,6501,2581,573438
Deferred revenue226226226
Deferred revenue and credits455455455
Contract with customer, liability226
Other liabilities     1986
Other undisclosed current liabilities   2,2851,9122,3762,979
Total current liabilities:6,11510,0218,2928,4389,97610,1607,605
Noncurrent Liabilities
Liabilities, other than long-term debt3,2433,4693,6953,9224,0914,5455,000
Deferred revenue and credits4,0914,5455,000
Deferred revenue3,2433,4693,695
Contract with customer, liability3,922
Other undisclosed noncurrent liabilities 3211131761,7733,401 
Total noncurrent liabilities:3,2433,7903,8084,0985,8647,9465,000
Total liabilities:9,35813,81112,10012,53615,84018,10612,605
Stockholders' equity
Stockholders' equity attributable to parent46,1206,17511,5745,387(11,691)4,29710,010
Common stock2091,8591,1125710868255
Additional paid in capital490,644432,858413,879387,238350,514342,484328,334
Accumulated other comprehensive income (loss)(14)14(18)(12)3(31)(22)
Accumulated deficit(444,719)(428,556)(403,399)(381,896)(362,316)(338,224)(318,557)
Stockholders' equity attributable to noncontrolling interest    830830830
Total stockholders' equity:46,1206,17511,5745,387(10,861)5,12710,840
TOTAL LIABILITIES AND EQUITY:55,47819,98623,67417,9234,97923,23323,445

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues2262312,1831,2287875,54611,456
Gross profit:2262312,1831,2287875,54611,456
Operating expenses(16,722)(25,224)(23,882)(24,510)(26,524)(29,249)(35,428)
Operating loss:(16,496)(24,993)(21,699)(23,282)(25,737)(23,703)(23,972)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
12481431,1513062(35)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes (208)631,5971,6283,988 
Loss from continuing operations before equity method investments, income taxes:(16,484)(25,153)(21,493)(20,534)(24,079)(19,653)(24,007)
Other undisclosed income from continuing operations before income taxes321      
Loss from continuing operations before income taxes:(16,163)(25,153)(21,493)(20,534)(24,079)(19,653)(24,007)
Income tax expense (benefit) (4)(10)124(13)(14)(16)
Net loss:(16,163)(25,157)(21,503)(20,410)(24,092)(19,667)(24,023)
Net income attributable to noncontrolling interest   163  44
Other undisclosed net loss attributable to parent   (326)   
Net loss available to common stockholders, diluted:(16,163)(25,157)(21,503)(20,573)(24,092)(19,667)(23,979)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(16,163)(25,157)(21,503)(20,410)(24,092)(19,667)(24,023)
Other comprehensive income (loss)(28)32(6)(15)34(9)(9)
Comprehensive loss:(16,191)(25,125)(21,509)(20,425)(24,058)(19,676)(24,032)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest   (163)  44
Comprehensive loss, net of tax, attributable to parent:(16,191)(25,125)(21,509)(20,588)(24,058)(19,676)(23,988)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: